Platelet to lymphocyte ratio (PLR) retains independent prognostic significance in advanced stage marginal zone lymphoma patients treated with rituximab, cyclophosphamide, vincristine, and prednisone combination chemotherapy (R-CVP): Consortium for Improving Survival of Lymphoma trial

BACKGROUND: Rituximab plus cyclophosphamide, vincristine, and prednisone (R-CVP) is one of the effective chemotherapeutic regimens for patients with advanced stage marginal zone lymphoma (MZL). However, prognostic factors that affect the outcome of treatment for MZL are not well understood. METHODS:...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Res
Main Authors: Seo, Jeongkuk, Kim, Won Seog, Kim, Jin Seok, Kim, Seok Jin, Lee, Jae Hoon, Hong, Jun Shik, Lee, Gyeong-Won, Oh, Sung Yong, Lee, Ji-Hyun, Yoon, Dok Hyun, Lee, Won-Sik, Kim, Hyo Jung, Kwak, Jae-Yong, Kang, Hye Jin, Jo, Jae-Cheol, Park, Yong, Lee, Ho Sup, Kim, Hyo-Jin, Suh, Cheolwon
Formato: Artigo
Idioma:Inglês
Publicado em: Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 2017
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5641512/
https://ncbi.nlm.nih.gov/pubmed/29043235
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5045/br.2017.52.3.200
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados